NEW YORK, Aug. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
U.S. Retinal Therapeutics Market
http://www.reportlinker.com/p0559274/US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment
This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the "Product Pipeline" section of this research service.
Table of Contents
C h a p t e r 1
Executive Summary
U.S. Retinal Therapeutics Market 1-1
Introduction 1-1
C h a p t e r 5
Appendix
Decision Support Databases 1-1
Total Population 1-1
Population Aged 15 to 24 Years 1-3
Population Aged 25 to 34 Years 1-5
Population Aged 35 to 44 Years 1-7
Population Aged 45 to 54 Years 1-9
Population Aged 55 to 64 Years 1-11
Population Above 45 Years 1-13
Population Above 65 Years 1-15
AMD Prevalence 1-17
AMD Incidence 1-20
Diabetes Prevalence 1-22
Diabetes Incidence 1-24
C h a p t e r 4
Market Analysis
Market Outlook and Revenue Forecasts 1-1
Age-related Macular Degeneration 1-1
WET AMD 1-1
Diabetic Retinopathy and Diabetic Macular Edema 1-18
ANTI-VEGFs 1-19
CORTICOSTEROIDS 1-24
OTHER LATE-STAGE CANDIDATES 1-33
Retinal Vein Occlusion 1-34
CORTICOSTEROIDS 1-34
ANTI-VEGFs 1-35
VEGF Trap-Eye 1-36
Competitive Overview 1-37
Competitive Structure 1-37
C h a p t e r 3
Treatment Overview and Product Pipeline
Treatment Overview 1-1
Age-Related Macular Degeneration 1-1
Product Analysis and Treatment Practices for AMD 1-1
Visudyne (Verteporfin) 1-1
Macugen (Pegaptanib) 1-2
Lucentis (Ranibizumab) 1-2
Avastin (Bevacizumab) 1-3
Other Treatment Practices 1-3
Diabetic Retinopathy and Diabetic Macular Edema 1-4
Current Treatments and Practices for Diabetic Retinopathy 1-4
Current Treatments and Practices for Diabetic Macular Edema 1-4
Retinal Vein Occlusion 1-5
Product Pipeline 1-6
Age-Related Macular Degeneration 1-6
Diabetic Retinopathy and Diabetic Macular Edema 1-8
Retinal Vein Occlusion 1-9
C h a p t e r 2
Market Introduction
Research Scope and Methodology 1-1
Scope and Segmentation 1-1
Research Methodology 1-2
Market Overview 1-2
Introduction 1-2
Disease Overviews 1-3
Age-Related Macular Degeneration 1-3
Diabetic Retinopathy and Diabetic Macular Edema 1-4
Retinal Vein Occlusion 1-5
Clinical Need and Burden of Disease 1-5
Age-related Macular Degeneration 1-5
Wet and Dry AMD Prevalence 1-5
Wet AMD Treated Patient Forecast 1-8
Diabetic Retinopathy and Diabetic Macular Edema 1-10
Diabetic Retinopathy 1-10
Diabetic Macular Edema 1-12
Retinal Vein Occlusion 1-13
Prevalence Rates: RVO, BRVO and CRVO 1-13
Treatable Patient Population 1-15
Market Trends 1-16
Market Engineering Measurements 1-16
Industry Challenges and Strategies 1-17
Off-Label Use of Avastin Significantly Suppresses Revenue Potential 1-18
Lengthy and Costly Clinical Trials Impede New Market Entrants 1-19
Developing Therapies to Treat Diseases of the Back-of-the-Eye is Complex 1-19
Established Treatment Alternatives Impede Success of New DME Therapies 1-19
Market Drivers 1-20
Worldwide Diabetes Epidemic Fuels Research into Vision-Compromising Comorbidities 1-20
Presence of Novel Biopharmaceuticals Boosts Market 1-21
Market Opportunity for Wet AMD Drugs Further Expanded by Penetration into other
Highly Lucrative Back-of-the-Eye Diseases 1-21
Advancements in Formulation Technology Opens New Routes to Revenue Generation 1-21
Aging Population to Significantly Increase Demand for Treatment 1-22
List of Figures
C h a p t e r 2
Market Introduction
2-1 Retinal Therapeutics Market:
Intermediate AMD and Advanced Dry AMD Prevalence Forecasts (U.S.), 2006-2016 1-6
2-2 Retinal Therapeutics Market:
Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-7
2-3 Retinal Therapeutics Market:
Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9
2-4 Retinal Therapeutics Market:
DR Prevalence Forecasts among All Diabetics and among Type I
Diabetics (U.S.), 2006-2016 1-11
2-5 Retinal Therapeutics Market:
Incidence and Treated Patient Forecasts for DME among Diagnosed
Diabetics (U.S.), 2006-2016 1-12
2-6 Retinal Therapeutics Market:
CRVO, BRVO, and Total RVO Prevalence Forecasts (U.S.), 2006-2016 1-14
2-7 Retinal Therapeutics Market:
BRVO, CRVO, and Total RVO Treatment-Eligible Patient Forecasts (U.S.), 2006-2016 1-15
2-8 Retinal Therapeutics Market:
Top Four Industry Challenges Ranked in Order of Impact (U.S.), 2011-2016 1-18
2-9 Retinal Therapeutics Market:
Market Drivers Ranked in Order of Impact (U.S.), 2011-2016 1-20
C h a p t e r 3
Treatment Overview and Product Pipeline
3-1 Retinal Therapeutics Market:
Wet AMD Pipeline Overview (U.S.), 2010 1-7
3-2 Retinal Therapeutics Market:
Dry AMD Pipeline Overview (U.S.), 2010 1-8
3-3 Retinal Therapeutics Market:
DR and DME Pipeline Overview (U.S.), 2010 1-9
3-4 Retinal Therapeutics Market:
RVO Pipeline Overview (U.S.), 2010 1-9
C h a p t e r 4
Market Analysis
4-1 Retinal Therapeutics Market:
Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2
4-2 Retinal Therapeutics Market:
Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4
4-3 Retinal Therapeutics Market:
Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6
4-4 Retinal Therapeutics Market:
Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7
4-5 Retinal Therapeutics Market:
VEGF Trap-EYE Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-10
4-6 Retinal Therapeutics Market:
Lucentis Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-12
4-7 Retinal Therapeutics Market:
Avastin Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-13
4-8 Retinal Therapeutics Market:
Total AMD Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-15
4-9 Retinal Therapeutics Market:
Product Market Share by Revenue - AMD Segment (U.S.), 2016 1-16
4-10 Retinal Therapeutics Market:
Product Market Share by Patients - AMD Segment (U.S.), 2016 1-17
4-11 Retinal Therapeutics Market:
Lucentis Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-21
4-12 Retinal Therapeutics Market:
Avastin Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-23
4-13 Retinal Therapeutics Market:
Iluvien Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-26
4-14 Retinal Therapeutics Market:
Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-28
4-15 Retinal Therapeutics Market:
Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-30
4-16 Retinal Therapeutics Market:
Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32
4-17 Retinal Therapeutics Market:
Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33
4-18 Retinal Therapeutics Market:
Competitive Structure (U.S.), 2010 1-38
C h a p t e r 5
Appendix
5-1 Decision Support Database:
Total Population in Million (World), 2004-2014 1-1
5-2 Decision Support Database:
Population Aged 15 to 24 Years in Million (World), 2004-2014 1-4
5-3 Decision Support Database:
Population Aged 25 to 34 Years in Million (World), 2004-2014 1-6
5-4 Decision Support Database:
Population Aged 35 to 44 years in Million (World), 2004-2014 1-8
5-5 Decision Support Database:
Population Aged 45 to 54 Years in Million (World), 2004-2014 1-10
5-6 Decision Support Database:
Population Aged 55 to 64 Years in Million (World), 2004-2014 1-12
5-7 Decision Support Database:
Total Population 45 Plus in Million (World), 2004-2014 1-14
5-8 Decision Support Database:
Population 65 Plus in Million (World), 2004-2014 1-16
5-9 Decision Support Database:
AMD Population in '000 (World), 2002-2012 1-18
5-10 Decision Support Database:
New Cases of AMD in '000 (World), 2002-2012 1-20
5-11 Decision Support Database:
Prevalence of Diabetes in '000 (World), 2002-2012 1-22
5-12 Decision Support Database: New Cases of Diabetes in '000 (World), 2002-2012 1-25
List of Charts
C h a p t e r 2
Market Introduction
2.1 Retinal Therapeutics Market:
Market Segmentation by Disease (U.S.), 2009 1-2
2.2 Retinal Therapeutics Market:
Advanced Dry AMD and Intermediate AMD Prevalence Forecasts (U.S.), 2006-2016 1-6
2.3 Retinal Therapeutics Market:
Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-8
2.4 Retinal Therapeutics Market:
Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9
2.5 Retinal Therapeutics Market:
DR Prevalence among All Diabetics and among Type I Diabetics (U.S.), 2006-2016 1-11
2.6 Retinal Therapeutics Market:
Incidence and Treated Patient Forecasts for DME among Diagnosed Diabetics
(U.S.), 2006-2016 1-13
2.7 Retinal Therapeutics Market:
Prevalence Forecasts for BRVO, CRVO and Total RVO (U.S.) 2006-2016 1-14
2.8 Retinal Therapeutics Market:
Treatment-Eligible Patient Forecasts for BRVO, CRVO and Total RVO (U.S.), 2006-2016 1-16
2.9 Retinal Therapeutics Market:
Market Engineering Measurements (U.S.), 2009 1-17
C h a p t e r 4
Market Analysis
4.1 Retinal Therapeutics Market:
Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2
4.2 Retinal Therapeutics Market:
Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4
4.3 Retinal Therapeutics Market:
Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6
4.4 Retinal Therapeutics Market:
Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7
4.5 Retinal Therapeutics Market: VEGF Trap-Eye Revenue and Growth Rate
Forecasts - AMD Segment (U.S.), 2006-2016 1-11
4.6 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate
Forecasts - AMD Segment (U.S.), 2006-2016 1-12
4.7 Retinal Therapeutics Market: Avastin Revenue and Growth Rate
Forecasts - AMD Segment (U.S.), 2006-2016 1-14
4.8 Retinal Therapeutics Market: Total AMD Revenue and Growth Rate
Forecasts - AMD Segment (U.S.), 2006-2016 1-15
4.9 Retinal Therapeutics Market: Product Market Share by
Revenue - AMD Segment (U.S.), 2016 1-16
4.10 Retinal Therapeutics Market: Product Market Share by
Patients - AMD Segment (U.S.), 2016 1-17
4.11 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate
Forecasts - DME Segment (U.S.), 2006-2016 1-22
4.12 Retinal Therapeutics Market: Avastin Revenue and Growth Rate
Forecasts - DME Segment (U.S.), 2006-2016 1-23
4.13 Retinal Therapeutics Market: Iluvien Revenue and Growth Rate
Forecasts - DME Segment (U.S.), 2006-2016 1-27
4.14 Retinal Therapeutics Market:
Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-29
4.15 Retinal Therapeutics Market:
Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-31
4.16 Retinal Therapeutics Market:
Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32
4.17 Retinal Therapeutics Market:
Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33
To order this report:
Machine Tool and Equipment Industry: U.S. Retinal Therapeutics Market
Machine Tool and Equipment Business News
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article